We caught up with Melissa Fauth, President and CEO, and Jeff Scott, Business Development Manager, to learn more about the exciting new PULVERISETTE 11 Knife Mill and ANALYSETTE 22 NeXT Particle Analyzer instruments.
We take a moment and examine a few new product trends that will help the industry gain stronger footholds in the new year and beyond.
Solubility, stability, dose release, and bioavailability -- progress in these areas is essential for the effectiveness of cannabis formulations, and the future of cannabis drug development moving forward.
The science behind the evolving world of cannabis-based pharmaceuticals will ultimately pave the way towards better, more effective treatments for a wide range of human conditions and disease.
Although barriers to research and roadblocks persist, important developments have opened the cannabis industry to new and exciting medical opportunities.
With hemp now legal in the US, it is worth reviewing the differences between CBD and THC -- which range far beyond chemical and pharmacological.
A growing number of studies have reported that cannabis use can diminish the negative and addictive effects of opioid use without sacrificing pain relief.
The study has interesting and exciting implications for the potential of cannabis-based neurodegenerative disease applications.
Stratifying the therapeutic value of cannabis compounds will continue to rely upon improvements in cannabis processing and testing methods and equipment.
Further evidence to support plant-based cannabis therapeutics as both effective and safe may have positive effects on the medical marijuana field as a whole.